Guidelines for bacteriophage product certification

Methods in Molecular Biology

Volumn 1693, Issue , 2018, Pages 253-268

  Fauconnier, Alan ^a,b  

^a Federal Agency for Medicines and Health Products Belgium   (Belgium)

^b Culture In Vivo ASBL   (Belgium)

Author keywords

Autogenous vaccine; Homologous group; Magistral formula; Multi strain dossier; Named patient; Personalized medicine; Phage therapy medicinal product; Regulatory framework

Indexed keywords

AUTOVACCINE; ANTIINFECTIVE AGENT;

BACTERIOPHAGE; CERTIFICATION; EUROPEAN; EUROPEAN MEDICINES AGENCY; EUROPEAN UNION; HUMAN; LICENSING; PERSONALIZED MEDICINE; PHAGE THERAPY; PRACTICE GUIDELINE; GOVERNMENT REGULATION; GROWTH, DEVELOPMENT AND AGING; LEGISLATION AND JURISPRUDENCE;

ANTI-BACTERIAL AGENTS; BACTERIOPHAGES; CERTIFICATION; GOVERNMENT REGULATION; GUIDELINES AS TOPIC; HUMANS;

EID: 85033662068     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4939-7395-8_19     Document Type: Chapter

References (41)

1. European Parliament and Council of the European Union (2012) Directive 2001/83/ EC on the community code relating to medicinal products for human use, as amended. http://ec.europa.eu/health/files/eudralex/vol-1/dir_2001_83_consol_2012/dir_2001_ 83_cons_2012_en.pdf. Accessed 24 Aug 2016
2. Chan BK, Abedon ST, Loc-Carillo C (2013) Phage cocktails and the future of phage therapy. Future Microbiol 8:769–783. doi:10.2217/fmb.13.47
3. Huys I, Pirnay JP, Lavigne R, Jennes S, De Vos D, Casteels M, Verbeken G (2013) Paving a regulatory pathway for phage therapy. EMBO Rep 14:951–954. doi:10.1038/embor.2013. 163
4. Pirnay JP, De Vos D, Verbeken G, Merabishvili M, Chanishvili N, Vaneechoutte M, Zizi M, Laire G, Lavigne R, Huys I, Van den Mooter G, Buckling A, Debarbieux L, Pouillot F, Azeredo J, Kutter E, Dublanchet A, Górski A, Adamia R (2011) The phage therapy paradigm: prêt-à--porter or sur-mesure? Pharm Res 28:934–937. doi:10.1007/s11095-010-0313-5
5. Chan BK, Abedon ST (2012) Phage therapy pharmacology phage cocktails. Adv Appl Microbiol 78:1–23. doi:10.1016/B978-0-12-394805-2.00001-4
6. Appropriate ICH Expert Working Group (2000) ICH Q7 Good manufacturing practice guide for active pharmaceutical ingredients. http://www.ich.org/fileadmin/Public_Web_ Site/ICH_Products/Guidelines/Quality/Q7/Step4/Q7_Guideline.pdf. Accessed 25 Nov 2016
7. European Commission (2014) Basic requirements for active substances used as starting materials. http://ec.europa.eu/health/files/eudralex/vol-4/2014-08_gmp_part1.pdf. Accessed 25 Nov 2016
8. European Medicines Agency (EMA) Compliance and Inspections Department (2014) Guidance for the template for the qualified person’s declaration concerning GMP compliance of active substance manufacture “The QP declaration template”. http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2014/06/WC500167852.pdf. Accessed 25 Nov 2016
9. Verbeken G, De Vos D, Vaneechoutte M, Merabishvili M, Zizi M, Pirnay JP (2007) European regulatory conundrum of phage therapy. Future Microbiol 2:485–491. doi:10.2217/17460913.2.5.485
10. Henein A (2013) What are the limitations on the wider therapeutic use of phage? Bacteriophage 3:e24872-1–e24872-7
11. Verbeken G, Pirnay JP, Lavigne R, Jennes S, De Vos D, Casteels M, Huys I (2014) Call for a dedicated European legal framework for bacteriophage therapy. Arch Immunol Ther Exp 62:117–129. doi:10.1007/s00005-014-0269-y
12. Verbeken G, Pirnay JP, De Vos D, Jennes S, Zizi M, Lavigne R, Casteels M (2012) Huys I. Optimizing the European regulatory framework for sustainable bacteriophage therapy in human medicine 60:161–172. doi:10.1007/s00005-012-0175-0
13. Cooper CJ, Khan Mirzaei M, Nilsson AS (2016) Adapting drug approval pathways for bacteriophage therapeutics. Front Microbiol 7: article 1209. doi:10.3389/fmicb.2016.01209
14. Fauconnier A (2017) Regulating phage therapy. EMBO Rep 2117:e201643250
15. European Medicines Agency (2015) Workshop on the therapeutic use of bacteriophages. http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/events/2015/05/event_detail_001155.jsp&mid=WC0b01 ac058004d5c3. Accessed 16 Nov 2016
16. Pelfrene E, Willebrand E, Cavaleiro Sanches A, Sebris Z, Cavaleri M (2016) Bacteriophage therapy: a regulatory perspective. J Antimicrob Chemother 71:2071–2074. doi:10.1093/jac/dkw083
17. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) (2003–2004) M4: the common technical document. http://www.ich. org/products/ctd.html. Accessed 23 Aug 2016
18. appropriate ICH Expert Working Group (1997) ICH Q5D derivation and characterisation of cell substrates used for production of biotechnological/biological products. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q5D/Step4/Q5D_Guideline.pdf. Accessed 6 Dec 2016
19. Food and Drug Administration - Center for Biologics Evaluation and Research (2010) Characterization and qualification of cell substrates and other biological materials used in the production of viral vaccines for infectious disease indications. http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Vaccines/UCM202439.pdf. Accessed 6 Dec 2016
20. appropriate ICH Expert Working Group (2005) ICH Q2(R1) validation of analytical procedures: Text and methodology. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q2_R1/Step4/Q2_R1__Guideline.pdf. Accessed 6 Dec 2016
21. European Parliament and Council of the European Union (2015) Directive 2001/18/ EC on the deliberate release into the environment of genetically modified organisms and repealing Council Directive 90/220/EEC, as amended. http://eur-lex.europa.eu/legal-con tent/EN/TXT/PDF/? uri=CELEX:02001L0018-20150402&rid=1. Accessed 24 Aug 2016
22. CVMP Immunologicals Working Party (2010) Guideline on data requirements for multi-strain dossiers for inactivated vaccines against avian influenza (AI), bluetongue (BT) and foot-and-mouth disease (FMD). http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/03/WC500077950.pdf. Accessed 6 Dec 2016
23. CHMP Biologics Working Party (2009) Guideline on allergen products: production and quality issues. http://www.ema.europa.eu/docs/en_GB/document_library/Scien tific_guideline/2009/09/WC500003333. pdf. Accessed 25 Aug 2016
24. Lorenz AR, Luttkopf D, May S, Scheurer S, Vieths S (2009) The principle of homologous groups in regulatory affairs of allergen products – a proposal. Int Arch Allergy Immunol 148:1–17. doi:10.1159/000151243
25. Artu Biologicals Europe b.v. (2014) Package leaflet for artuvetrin therapy. http://score. green-online.nl/wp1/wp-content/uploads/2016/03/Package-Leaflet-Artuvetrin-Ther apy-.pdf. Accessed 16 Nov 2016
26. Committee for Human Medicinal Products (CHMP) (2008) Guideline on human cell-based medicinal products. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003894.pdf. Accessed 16 Nov 2016
27. Appropriate ICH Expert Working Group (2009) ICH Q8(R2) pharmaceutical development. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Qual ity/Q8_R1/Step4/Q8_R2_Guideline.pdf. Accessed 30 Aug 2016
28. Medicines and Healthcare Products Regulatory Agency (MHRA) (2014) The supply of unlicensed medicinal products (“specials”), MHRA guidance note 14. https://www.gov. uk/government/uploads/system/uploads/attachment_data/file/373505/The_supply_ of_unlicensed_medicinal_products__specials_. pdf. Accessed 18 Nov 2016
29. Medicines and Healthcare Products Regulatory Agency (MHRA) (2013). MHRA questions and answers for specials manufacturer’s http://www.mhra.gov.uk/home/groups/comms-ic/docu ments/websiteresources/con326474.pdf. Accessed 18 Nov 2016
30. Court of Justice of the European Union (2013) Case-law T-301/12. http://curia.europa.eu/juris/document/document_print. jsf;jsessionid=9ea7d2dc30d5d9e627166f254 881bf68b0b49219d217.e34KaxiLc3qMb4 0Rch0SaxuOchj0?doclang=EN&text=&pa geIndex=0&part=1&mode=req&docid =157141&occ=first&dir=&cid=19189 3. Accessed 18 Nov 2016
31. Leyens L, Richer É, Melien Ø, Ballensiefen W, Brand A (2015) Available tools to facilitate early patient access to medicines in the EU and the USA: analysis of conditional approvals and the implications for personalized medicine. Public Health Genomics 18:249–259. doi:10. 1159/000437137
32. Johnston JD, Feldschreiber P (2013) Proposal for new European pharmaceutical legislation to permit access to custom-made anti-sense oligo-nucleotide medicinal products. Br J Clin Pharmacol 77:939–946. doi:10.1111/bcp.12250
33. Lacroix AS (2013) Place des autovaccins dans la lutte contre les maladies chez la animaux de rente. Dissertation, Ecole nationale vétérinaire d’Alfort and Faculté de médecine de Créteil. http://theses.vet-alfort.fr/telecharger.php? id=1537. Accessed 21 Nov 2016
34. Legifrance (2010) Article L5141–12 du code de la santé publique. https://www.legifrance. gouv.fr/affichCodeArticle.do;jsessionid=F187 5451A6DC245AD15E5AE3E6CA26B4.tpdil a11v_1?idArticle=LEGIARTI000021666207 &cidTexte=LEGITEXT000006072665&date Texte=20160901&categorieLien=id&oldAct ion=&nbResultRech=. Accessed 1 Sep 2016
35. Legifrance (2005) Décret n° 2005–374 du 20 avril 2005 relatif aux autovaccins à usage vétérinaire et modifiant le code de la santé publique (partie réglementaire). https://www. legifrance.gouv.fr/eli/decret/2005/4/20/SANP0520823D/jo/texte. Accessed 1 Sep 2016
36. Legifrance (2008) Arrêté du 6 mars 2008 relatif aux bonnes pratiques de préparation des autovaccins à usage vétérinaire. https://www. legifrance.gouv.fr/affichTexte.do?cidTexte =JORFTEXT000018392379&categorieLien =id. Accessed 1 Sep 2016
37. Justel (2002) Royal Decree of 19 December 2016, as amended http://www.ejustice.just. fgov.be/cgi_loi/change_lg.pl?language=fr& la=F&cn=1997121964&table_name=loi. Accessed 21 Nov 2016
38. Federal Agency for Medicines and Health Products (2016) Liste des laboratoires agréés belges. https://www.fagg-afmps.be/sites/default/files/content/Matieres_premieres/liste_labo_site_web_2016_11_08_validite.pdf, Accessed 21 Nov 2016
39. Scientific Institute of Public Health (2014) https://www.wiv-isp.be/en. Accessed 21 Nov 2016
40. Federal Agency for Medicines and Health Products (2016) Scientific-technical advice https://www.fagg-afmps.be/en/human_use/medicines/medicines/scientific_technical_ advice. Accessed 22 Nov 2016
41. Committee for Human Medicinal Products (CHMP) (2015) Guideline on influenza vaccines – submission and procedural requirements http://www.ema.europa.eu/docs/en_ GB/document_library/Regulatory_and_pro cedural_guideline/2015/07/WC500189035. pdf. Accessed 24 Nov 2016